BioNTech co-founders to establish new mRNA company by 2026
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall Street ends higher as US, Iran attacks ease; major tech-related shares jump
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Mizuho says ignore Apple noise, flags key catalyst for Micron and memory in H2
- EchoStar Prepares Dish DBS Bankruptcy Filing as Soon as Tuesday - WSJ
- Strategy stock jumps 7% as firm shifts to active capital management
- New leader board: Citi refreshes AI compute semiconductor picks
- Honeywell completes aerospace spin-off, splits into 3 companies
BioNTech and Co-Founders Announce Plan to Pursue Next-Generation mRNA Innovations in Co-Founders-Led New Company as BioNTech Advances Toward Becoming a Multi-Product Company by 2030
March 10, 2026 6:33 AM EDTBioNTech continues to sharpen its strategic focus on the growing late-stage clinical pipeline spanning immunomodulator, ADC and mRNA candidatesBioNTech co-founders Ugur Sahin and Özlem Türeci will establish an independent biotechnology company to research and develop next-generation mRNA innovations; management transition by end of 2026Both companies focus on distinct strategic priorities to maximize value for patients and shareholders, with BioNTech planning to contribute related rights and mRNA technologies to... More
